Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors:
SEC Accession No. 0001104659-24-119151
Filing Date
2024-11-14
Accepted
2024-11-14 16:53:53
Documents
1

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G  
1 primary_doc.xml SCHEDULE 13G 8949
  Complete submission text file 0001104659-24-119151.txt   10602
Mailing Address 130 MAIN ST. 2ND FLOOR NEW CANAAN CT 06840
Business Address 130 MAIN ST. 2ND FLOOR NEW CANAAN CT 06840 203-404-1172
Nantahala Capital Management, LLC (Filed by) CIK: 0001472322 (see all company filings)

EIN.: 201151760 | State of Incorp.: MA | Fiscal Year End: 1231
Type: SCHEDULE 13G

Mailing Address 26 LANDSDOWNE STREET CAMBRIDGE MA 02139
Business Address 26 LANDSDOWNE STREET CAMBRIDGE MA 02139 617-651-8851
Fulcrum Therapeutics, Inc. (Subject) CIK: 0001680581 (see all company filings)

EIN.: 474839948 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G | Act: 34 | File No.: 005-91080 | Film No.: 241463827
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)